Groundbreaking Saliva Test Offers Rapid Sepsis Detection for Newborns
At Dubai Future Week 2026, a team from Harvard University unveiled "Oriva," a pioneering diagnostic tool that could transform how doctors treat neonatal sepsis. Currently, diagnosing this life-threatening bloodstream infectionâwhich affects roughly 1.3 million infants annuallyârequires invasive blood cultures that can take up to five days to yield results. By shifting the diagnostic focus to saliva, Oriva promises to slash this timeframe to just two hours, significantly improving the chances of early intervention for vulnerable newborns.
The technology works by condensing the functionality of a massive, hospital-grade laboratory into a portable, user-friendly device. It features a simple collector, a disposable microfluidic disc, and a compact testing unit that uses centrifugal force to analyze markers of infection on-site. By removing the need for blood draws and laboratory transport, this innovation is specifically designed to bring high-quality diagnostic care to underserved regions, offering a life-saving, affordable solution for communities that previously lacked access to advanced medical infrastructure.